Ionis Pharmaceuticals (NASDAQ:IONS) will be announcing its earnings results before the market opens on Tuesday, November 6th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Tuesday, August 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.20). Ionis Pharmaceuticals had a negative net margin of 7.20% and a negative return on equity of 1.22%. The company had revenue of $117.75 million for the quarter, compared to the consensus estimate of $128.22 million. On average, analysts expect Ionis Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Ionis Pharmaceuticals stock opened at $51.70 on Monday. The company has a quick ratio of 8.34, a current ratio of 8.38 and a debt-to-equity ratio of 0.76. Ionis Pharmaceuticals has a 52 week low of $39.07 and a 52 week high of $57.92. The firm has a market cap of $7.10 billion, a PE ratio of 646.25 and a beta of 2.39.
A number of equities analysts have recently commented on the company. Stifel Nicolaus lowered their price target on Ionis Pharmaceuticals from $47.00 to $45.00 and set a “hold” rating for the company in a report on Tuesday, August 28th. ValuEngine raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday. Piper Jaffray Companies set a $50.00 target price on Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, September 24th. Morgan Stanley set a $45.00 target price on Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, October 3rd. Finally, Zacks Investment Research cut Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 9th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $53.86.
In other news, SVP C Frank Bennett sold 12,500 shares of the stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $49.54, for a total value of $619,250.00. Following the completion of the sale, the senior vice president now owns 31,896 shares of the company’s stock, valued at $1,580,127.84. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Brett P. Monia sold 16,493 shares of the stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $54.00, for a total value of $890,622.00. Following the completion of the sale, the chief operating officer now directly owns 24,834 shares of the company’s stock, valued at approximately $1,341,036. The disclosure for this sale can be found here. In the last three months, insiders sold 41,493 shares of company stock valued at $2,072,372. Insiders own 2.44% of the company’s stock.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Featured Story: How dollar cost averaging works
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.